GLP-1 medicines and the treatment of obesity GLP-1RAs led to weight loss investigations, with liraglutide 3 mg daily approved for weight loss in 2014, followed by semaglutide 2.4 mg weekly in 2021, and tirzepatide in 2023
(2024) A new framework for the diagnosis, staging and management of obesity in adults Dicker, Dror, et al
Generic metformin, also used to treat diabetes, is associated with utilization management tools in only 30% of ACA Marketplace plans, almost exclusively in the form of quantity limits
When to Use Caution With Glutathione Supplementation Important Note: If you experience increased fatigue, nausea, joint or muscle aches, or any other adverse reaction when taking glutathione, seek the attention of a functional medicine-trained dietitian or physician